allergenic protein components Ara h1, Ara h2, and Ara h3 at 60 months (p = 1.11x10 -5 , Fig 2B,  102 Supplementary Section 7) in the full set of LEAP participants adjusting for intervention. 103 104 When examining specific IgE to peanut, as well as the three major allergenic components 105 of peanut, we observe a progressive divergence in the upper end of the IgE distributions in 106 MALT1 carriers (Fig 2C) with two key observations to note. First, the intervention with peanut 107 exposure effectively reduced peanut-specific IgE irrespective of carrier status (truncated 108 distributions in Fig 2C, bottom panel) . Second, within the avoidance group, the levels of peanut-109 specific IgE between the carriers and non-carriers is markedly different; rs57265082 carriers
The Learning Early about Peanut Allergy (LEAP) trial (1, 2) motivated a change in 50 pediatric guidelines for the early introduction of dietary peanut as an effective strategy for the 51 prevention of peanut allergy. LEAP participants were presumed to be at increased risk for peanut 52 allergy(3), and dietary introduction of peanut protein beginning in the first four to eleven months 53 of life significantly decreased the frequency of peanut allergy later in childhood and modulated 54 the immune response to peanuts in this at-risk group (1) . To identify the genetic determinants of 55 peanut allergy in the LEAP participants, whole genome sequencing (WGS) was performed 56 (Supplementary Information Sections 1-2, Table S1 ). Following published standards for WGS 57 data (4) (Supplementary Information Sections 3-4) , there were 542 per protocol LEAP 58 participants available for genome-wide genetic association tests, including 49 with peanut 59 allergy, which was defined as a positive result on a double-blind placebo-controlled oral food 60 challenge at 60 months of age (Supplementary Information Section 1) . The de-convolution of 61 genetic ancestry aligns well with self-reported race/ethnicity (Supplementary Information 62 Section 5, Fig S1) . Given the high success of early introduction of dietary peanut in the LEAP 63 trial, 48 peanut allergy participants were from the peanut avoidance arm and only one from the 64 consumption arm (Table S1 ). Therefore, genome-wide association was assessed for peanut 65 allergy in the 275 participants from the avoidance arm (N=48 peanut allergic/N=227 non peanut 66 allergic) on a total of 4,444,069 single nucleotide variants (SNVs , Fig 1, Supplementary  67 Information Section 6, Fig S2) in a discovery analysis. Subsequent follow up of the peak 68 genetic signal(s) was extended to include the participants from the consumption arm (N=267) 69 with immunological quantitative traits of importance (Fig 2) to facilitate the examination of the 70 identified genetic loci in the context of the intervention. 71
72
The peak association for peanut allergy in the avoidance group was observed on 73 chromosome 18 (Fig 1A) mapping to the mucosa-associated lymphoid tissue lymphoma 74 translocation (MALT1) gene (Fig 1C, Table S2 ). The region (Chr18:56337602..56456191) 75 includes strong regulatory signatures for MALT1 expression as well as the expression of the 76 intergenic non-coding RNA (lincRNA), RP11-108P20.1 in the Genotype-Tissue Expression 77 (GTEx) data (Figs S3, S4) . However, the specific set of SNVs with p-value <10 -5 for peanut 78 allergy only have eQTL signatures for MALT1 ( Table S3 ). The peak associated SNV was 79 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT rs57265082 with an estimated Odds Ratio (OR) of 10.99, minor allele frequency (MAF) of 5.6%, 80 and p = 6.49x10 -8 . Gene-based analysis was performed across rare exonic SNVs (MAF ≤5%) 81 using SKAT (Tables S4 and S5 ). There was nominal association with either all rare exonic SNVs 82 (p = 0.0830) or all rare damaging exonic SNVs (p = 0.0828); however, with the inclusion of the 83 peak WGS variant, rs57265082, the gene-based evidence was very strong (p = 1.89x10 -10 ). 84
Conditioning on the peak SNV, rs57265082, shows that the observed common variant signal is a 85 single genetic locus within the region (Fig S5) . There are overall strong differences in the 86 clinical profiles of the MALT1 risk allele carriers compared to non-carriers within the peanut 87 avoidance participants (Table S6 ). MALT1 is not associated with baseline selection criteria of 88 egg allergy or eczema (p = 0.3241, and p=0.1626 respectively in the avoidance group), and the 89 association between peanut allergy and MALT1 is independent of these baseline selections 90 (Table S7) . We observe no association between the key filaggrin variant, R501X, documented to 91 play a role in eczema and peanut allergy (p=0.4014 and MAF of 3.6% in the avoidance group), 92 but recognize that our sample size of N=275 may be underpowered for this. 93
94
We observe a weaker association with rs57265082 to sensitization (at 60 months, 95 sensitization is defined as those with peanut-specific IgE ≥ 0.1 kU/liter) in the peanut avoidance 96 group (OR = 4.55, p = 0.0011). Additionally, the MALT1 locus remains significantly associated 97 with peanut allergy (p = 0.0003), even within the subset of sensitized participants in the peanut 98 avoidance group (Fig 2A) , supporting its role as a genetic risk factor for allergy and not only 99 sensitization. With the inclusion of the LEAP participants from the consumption arm (N=267), 100
MALT1 was found to be significantly associated with an IgE response to multiple specific peanut 101 M A N U S C R I P T
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within the peanut avoidance group had the highest peanut-specific IgE levels as compared to 111 non-carriers (Fig 2C, upper panel) . The mean titers of peanut-specific IgE were significantly 112 different between carriers vs non-carriers and by treatment group (interaction p = 1.86x10 -5 ), 113 even after adjusting for the baseline differences in peanut-specific IgE (Fig S6A) . Importantly, 114 this effect of MALT1 on peanut-specific IgE in the peanut avoidance group is independent of 115 total IgE (Fig S6B, p=2 .03x10 -5 for peanut-specific IgE and p=0.366 for total IgE). Finally, the 116 additional value of knowing rs57265082 carrier status in predicting an individual's likelihood of 117 allergy was evaluated, and rs57265082 was found to be an independent predictor of allergy in the 118 avoidance group (Fig S7) . 119
120
In this first report of the genetics of peanut allergy within the LEAP study, a key 121 biological candidate, the MALT1 gene, is implicated as an independent risk factor for peanut 122 allergy in the context of peanut avoidance. These associations are irrespective of sensitization 123 status (in Fig S7, sensitization at baseline is defined by skin prick positivity, and in Fig 2A,  124 sensitization at 60 months sensitization is defined as peanut-specific IgE ≥ 0.1 kU/liter), 125 supporting a relationship with progression to symptomatic allergy after peanut sensitization, a 126 disease pattern that is inhibited by early and continuous consumption of peanuts. MALT1 127 encodes a paracaspase that functions as a critical part of the CARMA1-BCL10-MALT1 (CBM) 128 complex, causing NF-KappaB activation in B and T cells in response to an antigen binding to the 129 B or T cell receptor(5). In T cells, this forms part of the signaling cascade leading to T cell 130 activation(6) and involves the two MALT1 isoforms, MALT1A and MALT1B(7). Given that our 131 top SNVs affect MALT1 expression, it is possible that these variants may predispose an 132 individual to greater allergic disease by altering MALT1 expression or affecting the ratio of 133 MALT1A to MALT1B, thus increasing Th2 differentiation after antigen presentation. Additional 134 genes encoding other members of the CBM complex do not show evidence for association within 135 our discovery data (Fig S8) . 136 137 MALT1 has not been implicated in prior genetic studies, and we are also unable to 138 replicate prior published associations (Table S8 ) (8, 9) . It is important to note that the prior 139 studies compare non-allergic controls to peanut-allergic subjects (8, 9) , and the genetic 140 associations identified in these likely represent risk of allergic sensitization and not specifically 141
In contrast, the LEAP study included only participants who were at high risk for 142 peanut allergy, many of whom were sensitized at baseline, and this unique ascertainment of the 143 LEAP study facilitates our ability to test specifically for the risk of peanut allergy. Yet another 144 singular advantage of the LEAP study is that we are able to interrogate the avoidance group 145 (high incidence of peanut allergy) and contrast this to the consumption group (low incidence of 146 peanut allergy) using quantitative immunological markers to identify the genetic determinants of 147 peanut allergy that are relevant in the absence of peanut exposure. This homogeneity of exposure 148 (i.e. avoidance) and ascertainment (i.e. baseline risk factors) within LEAP account for the ability 149 to detect a strong association with MALT1 despite the limited sample size of N=275 in the 150 discovery analysis; in fact the p-value of 6.49x10 -8 for the single variant tests is near the 151 Bonferroni threshold for GWAS significance (5x10 -8 ), and our gene-based analysis results in a p 152 = 1.89x10 -10 . Targeted genotyping of rs57265082 on additional LEAP participants, including the 153 non per protocol participants, does not change the results from the discovery sample 154 (Supplementary Section 8, Table S9 ). Furthermore, of the seven participants within the 155 consumption arm that had peanut allergy at baseline, three were MALT1 carriers (unadjusted OR 156 for peanut allergy at baseline in the LEAP consumption group = 5.3, p = 0.0188 using a Pearson 157 chi-square test). However, the lack of a suitable population to use as a replication group is a 158 major limitation of this study, and additional replication will be important to follow up on these 159 associations observed within LEAP. 160 161 One striking observation is the differing effect of MALT1 carrier status on peanut-specific 162 IgE patterns between the two intervention arms in LEAP. The introduction of dietary peanut as a 163 strategy for the prevention of peanut allergy is equally effective within carriers and non-carriers. 164
However, our results indicate that within the LEAP participants, MALT1 carriers from the peanut 165 avoidance group have the highest risk for peanut allergy (58.6% of carriers of the MALT1 variant 166 in the avoidance group go on to get peanut allergy in contrast to only 12.7% of the non-carriers, 167 Table S6 ). Coupled with the observations that 1) the acquisition of additional peanut antigen 168 target specificities in the IgE response is markedly increased in the MALT1 carriers and 2) this 169 peanut-specific IgE response is independent of total IgE, our findings support a genotype-170 phenotype relationship that implicates the MALT1 pathway in the allergic immune pathogenesis 171 of peanut allergy. 
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Genomic Research on the Learning Early about Peanut Allergy (LEAP) study 30
The LEAP study, described in detail previously (1) , was a randomized trial examining the 31 effect of early peanut exposure on infants at high risk for peanut allergy. The study (1) found that 32 early exposure to peanuts greatly decreased the likelihood of peanut allergy among both skin 33 prick test negative and skin prick test positive participants. Among the skin prick test negative 34 participants in the intention-to-treat population, 13.7% of the peanut avoidance group was 35 allergic to peanuts at 60 months of age compared to 1.9% of the peanut consumption group. This 36 finding was mirrored in the skin prick test positive intention-to-treat population, where 35.3% of 37 the peanut avoidance group was allergic to peanuts at 60 months of age compared to 10.6% of 38 the peanut consumption group. 39
All participants that completed the LEAP study, followed the protocol to avoid or 40 consume peanuts according to their randomization assignment, and consented to genetic studies 41 were included in our sample for this work (N=556). The final sample set, following quality 42 control as defined in Supplementary Section 3-4 below was N=542, as described in 43 Supplementary Table S1 . Cases were defined as participants with a positive oral food challenge 44 (OFC) to peanuts at 60 months of age. The OFC was a double-blind placebo-controlled 45 challenge consisting of a single 5g dose of peanut protein for participants who were not 46 suspected to be allergic on the basis of skin prick test values and other clinical characteristics and 47 a total of 9.4 g of peanut protein in increasing increments for the participants in LEAP that were 48 suspected to be allergic. In participants where the OFC was unavailable or the results were 49 inconclusive, allergy was determined using clinical factors including history of peanut specific 50 exposure, peanut-specific IgE levels, and skin prick test values (1) . 51
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Informed consent 52
The LEAP (1, 2) study was approved by the institutional review board at the National 53
Research Ethics Service Committee London-Fulham. In addition, informed written consent was 54 obtained from the parent or guardian of all participants. 55 M A N U S C R I P T
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All samples with sequencing were also genotyped on the Illumina Omni 2.5 Array as 75 described previously 5,6 . On the basis of concordance between the sequence and array genotype 76 calls, we removed 11 of the 556 samples from the dataset for poor quality DNA. We removed 1 77 additional sample for discrepancy between self-reported and genetic sex. Identity by descent 78 (IBD) was run on a set of linkage disequilibrium (LD) pruned SNVs using PLINK 1.9 (8); 2 79 samples were sequenced as identical (Z2>0.97) but not confirmed to be monozygotic twins and 80 were both removed from the analysis subset. The final sample size passing quality control used 81 for analysis was N=542. 82
Ancestry de-convolution of the LEAP study participants 83
We implemented protocols similar to those established for the 1000 Genomes Project 84 (TGP) reference populations in previous work (4) including the same set of 2179 TGP 85 individuals and a set of 218,340 LD pruned SNVs. We used the smartpca program, a part of the 86 EIGENSOFT package (9), to perform Principal Components Analysis (PCA) (Supplementary 87 Figure S1B ). The final association models included the first five principal components for 88 ancestry based on the scree plot shown in Supplementary Figure S1C . 89
Tests for association 90
For the primary outcome, we tested the hypothesis that peanut allergy among the peanut 91 avoidance group participants was associated with SNV genotype under an additive model 92 including 5 PCs, age in months at entrance into the LEAP study, and sex. Similar analyses were 93 done to test for the association between SNV genotype and allergy adjusted for baseline risk 94 factors, with baseline risk factors themselves, sensitization at 60 months, and for association with 95 the filaggrin variant R501X ( Supplementary Table S7 ). Analyses were run using PLINK 1.9 96 and PSEQ, a part of the PLINK/SEQ package ((8), https://atgu.mgh.harvard.edu/plinkseq/) . 97
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
and eczema at baseline. We found that adjustment for either egg allergy at baseline or eczema at 121 baseline did not meaningfully change the association between our top variants and peanut allergy 122 in the peanut avoidance group ( Supplementary Table S7 ). Additionally, we did not see a 123 significant association between our top variants and egg allergy or eczema in either the peanut 124 avoidance or consumption groups, suggesting that the association we see between MALT1 and 125 peanut allergy is not a marker for these baseline traits. 126
Analysis of quantitative correlates of peanut allergy with MALT1 carrier status 127
To test the association of MALT1 carrier status at rs57265082 and component spreading 128 of the IgE response to the specific peanut protein components Ara h1, Ara h2, and Ara h3 at 60 129 months, we used the Cochran-Mantel-Haenszel chi-square test. This test looks at the association 130 between component spreading and MALT1 across (or controlling for) the treatment assignment 131 using both groups. Using a multivariate ordinal logistic regression model, there is a significant 132 interaction effect between MALT1 carrier status and the randomized intervention when regressed 133 on component spreading at 60 months to Ara h1, Ara h2, and Ara h3 (p-value = 0.0053). Ara h 134 status was imputed to 0 for all participants with peanut-specific IgE <0. 1. 135 To evaluate the predictive value of MALT1 carrier status for peanut allergy in the LEAP 136 avoidance Group (N=275), we used a multivariate logistic regression model including MALT1 137 rs57265082 genotype, SCORAD, peanut SPT, and egg allergy at baseline compared to the model 138 omitting MALT1 as a predictor, and the AUC of each model was compared using a likelihood 139 ratio chi-square test. 140
In all cases MALT1 carrier status was modeled under the dominant model, comparing 141 those with the GG genotype (Non-carriers) to those carrying at least one T allele (Carriers with 142 genotype TG or TT). Because of the small number of TT genotypes, other models were not 143 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT appropriate ( Supplementary Table S10 ). Additionally, for all analyses including the 144 quantitative correlates of peanut allergy, the imputed version of rs57265082 was used to include 145 7 participants with genotype missing. 146
Inclusion of intention-to-treat (ITT) participants 147
We repeated the analysis of the association of peanut allergy with our top SNV, 148 rs57265082, with the addition of the non per protocol ITT participants from the LEAP study. 149
These non per protocol participants were not included in the original per protocol group, because 150 they deviated from the protocol of their assigned group (peanut avoidance or peanut 151 consumption). This was done to show that our results were not sensitive to their exclusion from 152 the discovery data. 153
All ITT participants without WGS were genotyped for MALT1 variant rs57265082 using 154 the MGB Pleiades assay (ELITech Group). The assay was validated using 4 CEPH DNAs, 2 155 with GG genotype and 2 with GT genotype. As no CEPH DNAs with TT genotype were 156 available, an additional validation was run with 88 healthy control individuals with genotypes as 157 follows: 73 GG, 14 GT, and 1 TT. In addition, each genotyping plate contained 2 wells each of 158 GT and TT DNA used as a reference for genotype calling. Finally, genotypes were confirmed by 159 Sanger sequencing using the SimpleSeq dye termination kit (Eurofins), and sequences traces 160 were manually read to confirm GT and TT genotypes. 161
A similar association was seen for peanut allergy with the MALT1 variant rs57265082 in 162 the total peanut avoidance group consisting of both the per protocol and ITT participants 163 (N=299; p=1.28x10 -7 ) ( Supplementary Table S9 ). 
